statistiche ricercatore

Nome	#
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies	90
An intronic mutation in MLH1 associated with familial colon and breast cancer.	89
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay	81
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal?	80
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.	76
Therapeutic Challenges in Tissue Engineering	72
MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system	65
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors	64
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib	63
Mutazioni nei geni del MMR e sindrome HNPCC: analisi in vitro della patogenicità delle varianti missenso	60
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type	51
null	31
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?	8
Totale	830

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	51	0	0	0	0	11	0	9	2	10	0	5	14
2020/2021	138	9	15	19	0	15	12	10	12	14	12	13	7
2021/2022	79	5	17	2	1	0	5	1	5	11	10	1	21
2022/2023	239	14	34	12	21	16	31	0	7	44	3	46	11
2023/2024	144	25	4	11	12	19	41	1	9	0	3	1	18
2024/2025	77	31	25	9	7	5	0	0	0	0	0	0	0
Totale													830